Date:5/18/2023		
Your Name:Louis	Cappelli	
Manuscript Title: Differences in clinical outcomes based on molecular markers in glioblastoma patients treated		
with concurrent tumor	r-treating fields and chemoradiation: exploratory analysis of the SPARE trial _	
Manuscript number (if	f known):CCO-22-123	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	NOVOCURE	Funded SPARE Trial: Grant No. 19-0065. Funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication
2	Grants or contracts from	Time frame: past X None	36 months
	any entity (if not indicated in item #1 above).		
3	Royalties or licenses	XNone	

4	Consulting fees	XNone			
5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
	-				
7	Support for attending meetings and/or travel	XNone			
8	Patents planned, issued or	_XNone			
	pending				
9	Participation on a Data	XNone			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	XNone			
	in other board, society,				
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	XNone			
	materials, drugs, medical				
	writing, gifts or other				
	services				
13	Other financial or non- financial interests	XNone			
DI					
riea	Please summarize the above conflict of interest in the following box:				
Th	The SPARE trial was funded by Novocure (Grant No. 19-0065)				
	,				
			╛		
Dlac	sa place an "V" poyt to the	following statement to indicate your agreements			

_X__ I certify that I have answered every question and have not altered the wording of any of the questions on this form

te:5/18/2023				
/our Name:Mehak Khan				
nuscript Title: Differences in clinical outcomes based on molecular markers in glioblastoma patients treated				
th concurrent tumor-treating fields and chemoradiation: exploratory analysis of the SPARE trial _				
nuscript number (if known):CCO-22-123				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_ NOVOCURE	Funded SPARE Trial: Grant No. 19-0065. Funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	X None		
	J			
5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus, manuscript writing or			
	educational events			
6	Payment for expert	X None		
	testimony			
7	Support for attending	XNone		
	meetings and/or travel			
0	Detents alanged issued as	V None		
8	Patents planned, issued or pending	_XNone		
	periang			
9	Participation on a Data	X None		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	XNone		
	in other board, society, committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	X None		
	·			
12	Receipt of equipment,	XNone		
	materials, drugs, medical writing, gifts or other			
	services			
13	Other financial or non-	XNone		
	financial interests			
Plea	Please summarize the above conflict of interest in the following box:			

Th	The SPARE trial was funded by Novocure (Grant No. 19-0065)	

_X__ I certify that I have answered every question and have not altered the wording of any of the questions on this form

Date:5/18/2023
Your Name: Allison Kayne
Manuscript Title: Differences in clinical outcomes based on molecular markers in glioblastoma patients treated
with concurrent tumor-treating fields and chemoradiation: exploratory analysis of the SPARE trial
Manuscript number (if known):CCO-22-123

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	NOVOCURE	Funded SPARE Trial: Grant No. 19-0065. Funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	XNone		
5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	XNone		
	testimony			
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or	_XNone		
	pending			
9	Participation on a Data	XNone		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	XNone		
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	XNone		
12	Receipt of equipment,	XNone		
	materials, drugs, medical			
	writing, gifts or other			
12	services Other financial or non-	V. None		
13	financial interests	XNone		
	illianciai interests			
Plea	Please summarize the above conflict of interest in the following box:			
1	he SPARE trial was funded by N	lovocure (Grant No. 19-0065)	

_X__ I certify that I have answered every question and have not altered the wording of any of the questions on this form

Date: 5/18/2023
Your Name: Spencer Poiset
Manuscript Title: Differences in clinical outcomes based on molecular markers in glioblastoma patients treated with concurrent tumor-treating fields and chemoradiation: exploratory analysis of the SPARE trial
Manuscript number (if known):CCO-22-123
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a

relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_ NOVOCURE	Funded SPARE Trial: Grant No. 19-0065. Funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	X_None	
4	Consulting fees	XNone	

		1		
5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	XNone		
	testimony			
7	Support for attending	XNone		
	meetings and/or travel			
8	Patents planned, issued or	_XNone		
0	pending	_XNone		
	pending			
9	Participation on a Data	X None		
9	Safety Monitoring Board or	XNOTIE		
	Advisory Board			
10		V Name		
10	Leadership or fiduciary role	XNone		
	in other board, society,			
	committee or advocacy group, paid or unpaid			
11	Stock or stock options	X None		
11	Stock of Stock options			
12	Receipt of equipment,	X None		
12	materials, drugs, medical	^NUITE		
	writing, gifts or other			
	services			
13	Other financial or non-	X None		
13	financial interests			
	manda micrests			
Diago summariza the above conflict of interest in the fellowing bove				
riea	Please summarize the above conflict of interest in the following box:			

The SPARE trial was funded by Novocure (Grant No. 19-0065)			

X I certify that I have answered every question and have not altered the wording of any of the questions on this Form.

Date:5/18/2023
Your Name:Ryan Miller
Manuscript Title: Differences in clinical outcomes based on molecular markers in glioblastoma patients treated
with concurrent tumor-treating fields and chemoradiation: exploratory analysis of the SPARE trial
Manuscript number (if known):CCO-22-123

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	NOVOCURE	Funded SPARE Trial: Grant No. 19-0065. Funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	X None		
5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or educational events			
6	Payment for expert	X None		
	testimony			
	,			
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or	_XNone		
	pending			
_				
9	Participation on a Data	XNone		
	Safety Monitoring Board or Advisory Board			
10	Leadership or fiduciary role	X None		
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	XNone		
12	Possint of aguinment	V None		
12	Receipt of equipment, materials, drugs, medical	XNone		
	writing, gifts or other			
	services			
13	Other financial or non-	XNone		
	financial interests			
Plea	Please summarize the above conflict of interest in the following box:			
т	The SPARE trial was funded by Novocure (Grant No. 19-0065)			

_X__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ate:5/18/2023
our Name:Ayesha Ali
lanuscript Title: Differences in clinical outcomes based on molecular markers in glioblastoma patients treated
rith concurrent tumor-treating fields and chemoradiation: exploratory analysis of the SPARE trial
Tanuscript number (if known):CCO-22-123

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_NOVOCURE	Funded SPARE Trial: Grant No. 19-0065. Funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

		I		
4	Consulting fees	XNone		
5	Payment or honoraria for	X None		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
6	educational events Payment for expert	X None		
U	testimony	XNone		
	,			
7	Support for attending meetings and/or travel	XNone		
	meetings and, or travel			
8	Patents planned, issued or	_XNone		
	pending			
_				
9	Participation on a Data Safety Monitoring Board or	XNone		
	Advisory Board			
10	•	X None		
	in other board, society,			
	committee or advocacy group, paid or unpaid			
11	Stock or stock options	XNone		
12	Receipt of equipment,	XNone		
	materials, drugs, medical writing, gifts or other			
	services			
13	Other financial or non-	XNone		
	financial interests			
Plea	Please summarize the above conflict of interest in the following box:			
Т	The SPARE trial was funded by Novocure (Grant No. 19-0065)			

_X__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:5/18/2023		
Your Name:Muneeb Niazi		
Manuscript Title: Differences in cli	inical outcomes based on m	nolecular markers in glioblastoma patients treated
with concurrent tumor-treating fields ar	nd chemoradiation: explora	tory analysis of the SPARE trial
Manuscript number (if known):	CCO-22-123	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_NOVOCURE	Funded SPARE Trial: Grant No. 19-0065. Funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pastXNone	Somonus
3	Royalties or licenses	XNone	

4	Consulting fees	XNone		
5	Payment or honoraria for	X None		
,				
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	XNone		
	testimony			
	,			
7	Support for attending	XNone		
′		XNone		
	meetings and/or travel			
8	Datants planned issued or	X None		
0	Patents planned, issued or	_XNone		
	pending			
9	Participation on a Data	XNone		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	X None		
10	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	XNone		
12	Receipt of equipment,	X None		
	materials, drugs, medical			
	writing, gifts or other			
	services			
12	Other financial or non-	V None		
13		XNone		
	financial interests			
Plea	Please summarize the above conflict of interest in the following box:			
T	The SPARE trial was funded by Novocure (Grant No. 19-0065)			
- 1				

_X__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 3/3/2023					
Your Name: Wenyin Shi					
•	lanuscript Title: Differences in clinical outcomes based on molecular markers in glioblastoma patients treated witl Oncurrent tumor-treating fields and chemoradiation: exploratory analysis of the SPARE trial				
Manuscript number (if known):	CCO-22-123				
related to the content of your manuscrip parties whose interests may be affected	ou to disclose all relationships/activities/interests listed below that are ot. "Related" means any relation with for-profit or not-for-profit third by the content of the manuscript. Disclosure represents a commitment vindicate a bias. If you are in doubt about whether to list a				

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	NOVOCURE	Funded SPARE Trial: Grant No. 19-0065. Funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication		
	Time frame: past 36 months				
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone			
3	Royalties or licenses	XNone			

		1	Ι
4	Consulting fees	Brainlab	paid to me
		Novocure	paid to me
		Varian	paid to me
		Zai lab	paid to me
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
	pending		
9	Participation on a Data	X None	
,	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		

Please summarize the above conflict of interest in the following box:

WS reports consulting fees from Brainlab, Novocure, Varian, and Zai l (Grant No. 19-0065).	ab. The SPARE trial was funded by Novocure

Please place an "X" next to the following statement to indicate your agreement:

__X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: March 3, 2023
Your Name: Iyad Alnahhas

Manuscript Title: Differences in clinical outcomes based on molecular markers in glioblastoma patients treated with

concurrent tumor-treating fields and chemoradiation: exploratory analysis of the SPARE trial

Manuscript number (if known): CCO-22-123

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
Time frame: Since the initial planning of the work					
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	NOVOCURE	Funded SPARE Trial: Grant No. 19-0065. Funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication		
	Time frame: past 36 months				
2	Grants or contracts from any entity (if not indicated in item #1 above).	Novocure (Iyad Alnahhas)	(not relevant to this publication)		
3	Royalties or licenses	XNone			

4	Consulting fees	X None	
4	Consulting rees	XNOTIE	
5	Payment or honoraria for	X None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
-	educational events	V N	
6	Payment for expert testimony	XNone	
	testimony		
7	Support for attending	X None	
′	meetings and/or travel		
	, , , , , , , , , , , , , , , , , , ,		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11		V None	
11	Stock or stock options	XNone	
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

Please summarize the above conflict of interest in the following box:

IA reports grants or contracts from Novocure. The SPARE trial was funded by Novocure (Grant No. 19-0065).			

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.